NEW YORK (GenomeWeb News) - Ipsogen said today it has inked a pact with DNAVision that allows DNAVision to offer tests based on Ipsogen’s breast cancer gene profiles in a CLIA environment.
Ipsogen has a portfolio of diagnostics for blood cancers that are registered in Europe as IVDs. The company said that the agreement with DNAVision enables it to launch “a new generation of IVD profiling diagnostic products addressing unmet needs in guiding breast cancer therapies.”
DNAVision will offer Ipsogen’s microarray profiling services “at the level of quality of quantitative PCR,” Ipsogen said.
Financial terms of the agreement were not released.